HIGHLIGHTS
- who: Coronary Syndrome and colleagues from the Department of Cardiology, StAntonius Hospital, CM Nieuwegein, The Netherlands have published the Article: Clinical Medicine, in the Journal: (JOURNAL)
- what: In ACS [9,10], have been developed, such as fondaparinux, a pentasaccharide with indirect anti-factor Muchand progress has beenamade the field ofinhibitor. antithrombotic drugs in ACSsubstantial in recent years.
- how: This review discusses recently introduced and currently developed antiplatelet and anticoagulant drugs in ACS treatment. Previously PAR1 inhibitors such as vorapaxar showed great promise as 10 of 18 an antiplatelet agent that in preclinical studies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.